FWDI

Forward Industries, Inc. - 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for the period ended December 31, 2008. Forward Industries, Inc. designs, markets, and distributes custom soft-sided carrying cases for portable electronic devices, primarily blood glucose monitoring kits for diabetic patients and other consumer electronics. The company operates as a smaller reporting company with no long-term debt outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% ($0.35 million) driven by a 16% increase in diabetic product sales ($4.1 million vs. $3.5 million). This was partially offset by a decline in "other products" (primarily cell phone cases), which fell $0.2 million.
• Margin Compression: Gross profit decreased 16% to $0.94 million. Gross margin dropped from 22.6% to 17.8% due to higher costs associated with relocating the Hong Kong facility, staffing changes, and increased compliance and travel costs.
• Expense Reduction: Operating expenses decreased 23% ($0.37 million) to $1.34 million. This improvement was primarily due to the expiration of employment agreements for two executives in the prior year (saving ~$0.3 million in compensation/severance) and the elimination of minimum royalty payments to Motorola following a December 2008 amendment.
• Cash Flow: Operating cash flow turned negative, using $1.33 million compared to generating $1.05 million in the prior year. This was driven by a net loss and a $1.2 million increase in accounts receivable and inventory to support sales and production ramp-up for the Chinese New Year.

Outlook, Risks, and Contingencies

• Economic Environment: Management cites deteriorating economic conditions and financial market uncertainty as adverse factors impacting consumer spending and OEM order flows. They anticipate a challenging business environment to continue.
• Customer Concentration: Sales are highly concentrated among a few large OEM customers (e.g., Abbott Labs, Bayer, Lifescan, Roche). Variability in order flow from these customers creates significant revenue volatility.
• Motorola License: The company entered a new license agreement with Motorola in May 2008, amended in December 2008 to reduce the royalty rate from 15% to 7% and eliminate minimum royalty obligations for the period ending March 31, 2009. The company has notified Motorola of its intention not to renew the agreement upon expiration.
• Liquidity: The company maintains a strong liquidity position with $18.4 million in cash and no short-term or long-term debt. A $400,000 uncommitted credit line exists for a Swiss subsidiary, though it is partially encumbered by a letter of credit.
• Inventory Risk: Inventory allowances for obsolete goods were approximately $228,000 as of December 31, 2008. Management notes that customer defaults or returns could necessitate additional write-downs.

Investor Verification Checklist

• Verify the sustainability of the 16% growth in diabetic product sales given the reported decline in sales to the largest customer, Lifescan.
• Monitor the impact of the Motorola license expiration in March 2009 on future revenue streams and royalty obligations.
• Assess the trend in gross margins, specifically the impact of the Hong Kong facility relocation costs and whether these are one-time or recurring.
• Review the aging of accounts receivable, which increased by $1.25 million, to ensure collectibility in the current economic climate.
• Confirm the status of the $4.2 million in undistributed foreign earnings and the tax implications of potential repatriation.